Celyad Oncology Announces the Publication of Data From Its Phase 1 THINK Study of CYAD-01
February 09 2023 - 1:00AM
Business Wire
Regulatory News:
Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a
biotechnology company focused on the discovery and development of
innovative technologies for chimeric antigen receptor (CAR) T-cell
therapies, today announces the publication of the data from the
haematological arm of the THINK study which evaluated CYAD-01 in
relapsed or refractory (r/r) acute myeloid leukaemia (AML) and
myelodysplastic syndromes (MDS) or multiple myeloma (MM) patients.
The findings were published in the journal The Lancet
Haematology.
CYAD-01 is the Company’s first autologous CAR T-cell candidate,
based on the natural killer receptor NKG2D, assessed clinically.
The completed THINK study was an open-label, dose-escalation Phase
1 study for patients with r/r AML, MDS, or MM, after at least one
previous line of therapy. Patients were recruited from five
hospitals in the USA and Belgium.
The Lancet Haematology publication includes data from the 16
patients treated with CYAD-01 in the dose escalation segment of the
study, which evaluated three dose levels of CYAD-01 using a
schedule of three infusions at two-week intervals in the absence of
any preconditioning chemotherapy. Overall, CYAD-01 showed
favourable safety data with signs of clinical activity with three
of the 12 evaluable AML/MDS patients presenting an objective
response.
Importantly, the THINK study is one of the first completed
dose-escalation CAR T-cell studies in r/r AML/MDS. Unlike the
majority of the studies evaluating CAR T-cell therapy candidates,
the THINK study evaluated multiple infusions of CYAD-01 as a
stand-alone product candidate (i.e., without prior bridging or
preconditioning chemotherapy). This feature is of particular
interest considering the median older age and the poorer general
condition of patients with r/r AML or MDS at diagnosis.
Although the need to improve the anti-tumour activity is
warranted, these data in a difficult-to-treat patient population
potentially provide the proof-of-concept of targeting NKG2D ligands
by a CAR T-cell product candidate, and support the further
development of NKG2D-based CAR T-cell therapies.
About Celyad Oncology
Celyad Oncology is a biotechnology company focused on the
discovery and development of innovative technologies for chimeric
antigen receptor (CAR) T-cell therapies. The Company is focusing on
opportunities to fully harness the true potential of its
proprietary technology platforms and intellectual property and
support the development of next-generation CAR T candidates in
solid tumors and hematological malignancies. Celyad Oncology is
based in Mont-Saint-Guibert, Belgium and New York, NY. For more
information, please visit www.celyad.com.
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, statements regarding the potential safety,
activity, and feasibility of CYAD-01 cell therapy and other product
NKG2D-based candidates or the clinical and commercial potential of
these product candidates. The words “potential,” “target” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
release are based on management’s current expectations and beliefs
and are subject to a number of known and unknown risks,
uncertainties and important factors which might cause actual
events, results, financial condition, performance or achievements
of Celyad Oncology to differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks related to the
material uncertainty about the Company’s ability to continue as a
going concern; the Company’s ability to realize the expected
benefits of its updated strategic business model; the Company’s
ability to develop its IP assets and enter into partnerships with
outside parties; the Company’s ability to enforce its patents and
other IP rights; the possibility that the Company may infringe on
the patents or IP rights of others and be required to defend
against patent or other IP rights suits; the possibility that the
Company may not successfully defend itself against claims of patent
infringement or other IP rights suits, which could result in
substantial claims for damages against the Company; the possibility
that the Company may become involved in lawsuits to protect or
enforce its patents, which could be expensive, time-consuming, and
unsuccessful; the Company’s ability to protect its IP rights
throughout the world; the potential for patents held by the Company
to be found invalid or unenforceable; and other risks identified in
Celyad Oncology’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in the latest Annual Report on Form
20-F filed with the SEC and subsequent filings and reports by
Celyad Oncology. These forward-looking statements speak only as of
the date of publication of this document and Celyad Oncology’s
actual results may differ materially from those expressed or
implied by these forward-looking statements. Celyad Oncology
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230208006012/en/
Celyad Oncology: Investors: David Georges VP Finance and
Administration investors@celyad.com
Media: Caroline Lonez R&D Communications and Business
Development communications@celyad.com
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Sep 2023 to Sep 2024